Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5,528 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.
Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Miller T, Fisher E, Sandbrink R, Lake SL, Margolin DH, Oyuela P, Panzara MA, Compston DA; CARE-MS II investigators. Coles AJ, et al. Among authors: miller t. Lancet. 2012 Nov 24;380(9856):1829-39. doi: 10.1016/S0140-6736(12)61768-1. Epub 2012 Nov 1. Lancet. 2012. PMID: 23122650 Clinical Trial.
Quality of Life Improves with Alemtuzumab Over 6 Years in Relapsing-Remitting Multiple Sclerosis Patients with or without Autoimmune Thyroid Adverse Events: Post Hoc Analysis of the CARE-MS Studies.
Bertolotto A, Arroyo R, Celius EG, Comi G, Havrdova EK, Honeycutt WD, Hunter SF, Izquierdo G, Kornek B, Miller T, Mitsikostas DD, Singer BA, Ziemssen T, Chung L, Daizadeh N, Afsar S, Hashemi L, Senior P. Bertolotto A, et al. Among authors: miller t. Neurol Ther. 2020 Dec;9(2):443-457. doi: 10.1007/s40120-020-00191-7. Epub 2020 May 14. Neurol Ther. 2020. PMID: 32410147 Free PMC article.
Ofatumumab versus Teriflunomide in Multiple Sclerosis.
Hauser SL, Bar-Or A, Cohen JA, Comi G, Correale J, Coyle PK, Cross AH, de Seze J, Leppert D, Montalban X, Selmaj K, Wiendl H, Kerloeguen C, Willi R, Li B, Kakarieka A, Tomic D, Goodyear A, Pingili R, Häring DA, Ramanathan K, Merschhemke M, Kappos L; ASCLEPIOS I and ASCLEPIOS II Trial Groups. Hauser SL, et al. N Engl J Med. 2020 Aug 6;383(6):546-557. doi: 10.1056/NEJMoa1917246. N Engl J Med. 2020. PMID: 32757523 Clinical Trial.
Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial.
Foley JF, Defer G, Ryerson LZ, Cohen JA, Arnold DL, Butzkueven H, Cutter G, Giovannoni G, Killestein J, Wiendl H, Smirnakis K, Xiao S, Kong G, Kuhelj R, Campbell N; NOVA study investigators. Foley JF, et al. Lancet Neurol. 2022 Jul;21(7):608-619. doi: 10.1016/S1474-4422(22)00143-0. Epub 2022 Apr 25. Lancet Neurol. 2022. PMID: 35483387 Clinical Trial.
Satisfaction with alemtuzumab in relapsing multiple sclerosis patients: Results from the real-world PRO-ACT study.
Wray S, Jacques F, Miller TA, Nicholas JA, Arroyo R, Travis L, Khatri B, Chirieac M, Gandhi R, Roesch N, Rodrigues A, Melas-Melt L, Rawlings AM, Hunter SF. Wray S, et al. Mult Scler J Exp Transl Clin. 2022 Nov 15;8(4):20552173221135888. doi: 10.1177/20552173221135888. eCollection 2022 Oct-Dec. Mult Scler J Exp Transl Clin. 2022. PMID: 36407472 Free PMC article.
Rebif(®) Quality of Life (RebiQoL): A randomized, multicenter, Phase IIIb study evaluating quality-of-life measures in patients receiving the serum-free formulation of subcutaneous interferon beta-1a for the treatment of relapsing forms of multiple sclerosis.
Bandari D, Wynn D, Miller T, Singer B, Wray S, Bennett R, Hayward B, Dangond F; RebiQoL Study Group. Bandari D, et al. Among authors: miller t. Mult Scler Relat Disord. 2013 Jan;2(1):45-56. doi: 10.1016/j.msard.2012.07.005. Epub 2012 Sep 25. Mult Scler Relat Disord. 2013. PMID: 25877454
Share of Adult Suicides After Recent Jail Release.
Miller TR, Weinstock LM, Ahmedani BK, Carlson NN, Sperber K, Cook BL, Taxman FS, Arias SA, Kubiak S, Dearing JW, Waehrer GM, Barrett JG, Hulsey J, Johnson JE. Miller TR, et al. JAMA Netw Open. 2024 May 1;7(5):e249965. doi: 10.1001/jamanetworkopen.2024.9965. JAMA Netw Open. 2024. PMID: 38728036
5,528 results